Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in microglia (120 nCPM) | 1.00 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 3 pathways; mostly lysosome and autophagy | 1.00 |
Knock down and overexpress LPAR5 in microglia; measure glucocerebrosidase (GCase) activity and LC3-II and p62 flux and uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release).
- Cell type
- microglia
- Direction
- Both arms: public data does not say which way helps.
- Molecular readout
- glucocerebrosidase (GCase) activity and LC3-II and p62 flux
- Functional readout
- uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release)
- Rule-out
- If neither arm moves glucocerebrosidase (GCase) activity by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of LPAR5 in iPSC-derived microglia (iMGL); n = 3 differentiations; readouts: glucocerebrosidase (GCase) activity and LC3-II and p62 flux; uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release). Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- LPAR5 in dopamine neurons, braak+0.00 (p 1.000) → -0.40 (p 0.292)receipt 14272
- LPAR5 in microglia, braak-0.69 (p 0.038) → +0.45 (p 0.222)receipt 14271
Swarm cases
receipt 14272: LPAR5 in dopamine neurons, braak
- power
- full sample -0.24 (p 0.337, n 18), 95% CI -0.64 to +0.26. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.21 (p 0.393, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.28 (p 0.254, n 18). could be the mix.
- skeptic
- leave-one-out range -0.43 to -0.17, sign flips 0; without severely affected donors -0.24 (p 0.337, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for LPAR5 in dopamine neurons.
case closed: nothing better to follow up.
receipt 14271: LPAR5 in microglia, braak
- power
- full sample -0.08 (p 0.761, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.04 (p 0.881, n 18). does not hold up.
- composition
- microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.02 (p 0.928, n 18). could be the mix.
- skeptic
- leave-one-out range -0.21 to +0.04, sign flips 3; without severely affected donors -0.08 (p 0.761, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for LPAR5 in microglia.
case closed: nothing better to follow up.
Receipts
loading the receipts